Clinical trials: BK Viremia
Polyomavirus Infections, BK Viremia
Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant
The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%.
- Conditions
- Polyomavirus Infections, BK Viremia, Liver Transplant Infection, Kidney Transplant Infection
- Trial name
- NCT05224583
- Testing
- Simultaneous Liver-Kidney Transplant
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Methodist Health System
BK Polyomavirus, Kidney Transplant
Study of Anti-BKPyV Immune Responses in Kidney Transplant Patients With BKPyV Viremia
The human pathogen BK polyomavirus (BKPyV) is a ubiquitous, small, non-enveloped DNA virus that infects over 90% of people, typically in childhood with mild or no symptoms.
- Trial name
- NEPHRO-BK (NCT06988072)
- Testing
- blood sampling
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
BK Viremia, Kidney Transplant Infection
A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients
BEAT-BK will see the effect of immunosuppression reduction/modification with and without IVIG on BKPyV infection, allograft function, allograft loss, acute transplant rejection, immunosuppression load and death in kidney and…
- Conditions
- BK Viremia, Kidney Transplant Infection, Kidney Transplant Failure and Rejection
- Trial name
- BEAT-BK (NCT05325008)
- Testing
- Immunosuppression reduction/modification + intravenous immunoglobulin, Immunosuppression reduction/modification
- Where
- 13 sites in Australia
- Volunteers
- 280 people
- Sponsor
- The University of Queensland